pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
108
stories
9h
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
10h
Replimune melanoma drug wins support of FDA panel
biopharma dive
13h
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
16h
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
16h
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
17h
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines
endpoints
21h
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22h
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
fiercebiotech
23h
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
1d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
1d
Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policy
stat
1d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
1d
MapLight CEO on what investors missed in the biotech’s schizophrenia data
biopharma dive
1d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
1d
GSK cost-cutting plan includes global layoffs
biospace
2d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
3d
MapLight dives despite positive data for schizophrenia drug
biopharma dive
3d
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
biospace
3d
MapLight shares sink on mixed phase 2 schizophrenia readout
fiercebiotech
3d
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
4d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
4d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
5d
Anthropic’s life science plans; Novartis CEO on China deals; and more
endpoints
6d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
7d
Scancell to go public after winning reverse merger bid for troubled Neuphoria
fiercebiotech
8d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
8d
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
8d
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
9d
AI data becomes sticking point in biopharma dealmaking
biospace
9d
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
biopharma dive
← prev
page 1 of 4
next →
